- Active not recruitingPHASE2
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
This study looks at new ways to treat a type of breast cancer called HER2-positive. We're testing if using special drugs (Herceptin and Perjeta) without chemotherapy first can shrink tumours effectively. We're also checking if scans can predict how well treatments work.
For: Breast CancerBelgium · France · Germany - Active not recruitingPHASE3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
This study looks at a new combination of medicines, savolitinib and osimertinib, for people with a type of lung cancer that has gotten worse after treatment with osimertinib. It compares this new combination to standard chemotherapy to see if it works better and is safe.
For: Carcinoma · Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruiting
Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy
This study looks at how young children with a type of brain tumour called ependymoma respond to standard chemotherapy. It also checks for long-term side effects to help doctors improve treatment for them in the future.
For: Brain and Central Nervous System Tumors · Cognitive/Functional Effects · Long-term Effects Secondary to Cancer Therapy in ChildrenUnited Kingdom - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
For: Non-small Cell Lung CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
Paediatric Hepatic International Tumour Trial
This study, called PHITT, is for children and young people up to 30 years old with liver cancers called hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It aims to find better ways to treat these cancers by using tailored treatments and studying them closely.
For: Hepatoblastoma · Carcinoma, HepatocellularAustria · Belgium · Czechia - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - Active not recruitingPHASE3
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
This study compares two treatments for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded well to initial treatment. One treatment is a standard chemotherapy, and the other adds a new drug, polatuzumab vedotin, to that standard treatment.
For: Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-Cell LymphomaAustria · Germany · Spain - RecruitingPHASE1, PHASE2
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
This study looks at new ways to treat head and neck cancer using a drug called Amivantamab, sometimes combined with other treatments. It aims to find out if these treatments are safe and how well they work for people with different types of head and neck cancer.
For: Squamous Cell Carcinoma of Head and NeckUnited States · China · France - Active not recruitingPHASE2
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
This study is testing a new drug, BNT327, for advanced breast cancer (called triple-negative). Researchers want to see if it's safe and works well when given with chemotherapy. It's for people whose cancer has spread or is difficult to treat.
For: Locally Advanced Breast Cancer · Triple Negative Breast Cancer · Metastatic Triple Negative Breast CancersUnited States · Australia · Turkey (Türkiye) - Active not recruitingPHASE1, PHASE2
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This study is looking into a new drug, AZD5305, by itself or with other cancer treatments, for advanced solid cancers like ovarian, breast, and lung cancer. It aims to see if it's safe, tolerable, and effective.
For: Ovarian Cancer · Breast Cancer · Pancreatic CancerUnited States · Australia · Canada - RecruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
For: Carcinoma, Non-Small-Cell Lung · Neoplasm MetastasisUnited States · Australia · Austria - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
For: Small Cell Lung Cancer (SCLC) · Extensive-stage Small Cell Lung Cancer (ES-SCLC)United States · Argentina · Australia - RecruitingPHASE2, PHASE3
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
This study compares a new medicine, Iza-bren, with standard chemotherapy for advanced bladder cancer that has worsened after immunotherapy. It aims to see if Iza-bren is a better option for people who have already had certain treatments for their cancer.
For: Urothelial CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - Not yet recruitingPHASE3
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
This study for advanced neuroendocrine cancer compares a new drug called obrixtamig with standard chemotherapy. It aims to see if adding obrixtamig helps people live longer and also tests a new device to measure a cancer marker.
For: Extrapulmonary Neuroendocrine CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
For: Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal NeoplasmsUnited States · Australia · Austria - RecruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
This study looks at new drug combinations for a specific type of advanced lung cancer. It compares a new drug, Divarasib, with Pembrolizumab, against standard treatments to see which works best and is safest for patients with KRAS G12C-mutated non-small cell lung cancer.
For: Non-Small Cell Lung Cancer · KRAS G12C Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
For: Malignant Solid Tumor · Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC)United States · Denmark · France - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
This study is looking into a new drug, zipalertinib, for people with a certain type of lung cancer (NSCLC) in its early stages. It compares zipalertinib with standard chemotherapy to a dummy pill (placebo) with standard chemotherapy after surgery.
For: NSCLC, Stage IB-IIIA · Lung Cancer · AdjuvantUnited States · Argentina · Australia - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
For: Non-small Cell Lung Cancer · NSCLCUnited States · Argentina · Austria - Active not recruitingPHASE1
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
This study looks at a new drug, Amivantamab, alone or with other treatments, for certain types of advanced lung cancer. We want to find the safest and most effective dose, and see how well it works.
For: Non-Small-Cell Lung CancerUnited States · Australia · Canada - RecruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
For: Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate CancerUnited States · Canada · China - RecruitingPHASE1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This study looks at a new drug, BNT116, for advanced lung cancer. It explores if BNT116 is safe, how much to give, and how well it works when used alone or with other treatments for different types of non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Australia · Germany - Active not recruitingPHASE3
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
This study looks at new drug combinations for advanced bladder cancer that hasn't been treated before. It compares them to standard chemotherapy to see if they're safer and work better.
For: Urothelial CancerUnited States · Australia · Austria - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
This study is looking at new ways to treat advanced non-small cell lung cancer (a type of lung cancer) that has spread. It compares an experimental drug, rilvegostomig, with a standard drug, pembrolizumab, both given with chemotherapy, to see which works better and is safer.
For: Non-squamous Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
This study looks into adding a short course of chemotherapy (Paclitaxel and Carboplatin) before standard chemoradiation for women with locally advanced cervical cancer. The aim is to see if this extra step improves how long women live and if the cancer stays away.
For: Cervical CancerBrazil · India · Italy - RecruitingPHASE3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This study is looking into a new drug called Pumitamig for people with a type of breast cancer called triple-negative breast cancer. It compares Pumitamig plus standard chemotherapy with a dummy drug (placebo) plus chemotherapy to see if it's safe and effective.
For: Breast NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
This study is looking into a new medicine called Volrustomig for various advanced cancers, including cervical, head and neck, oesophageal, and mesothelioma. It aims to see how well it works and if it's safe, both on its own and with standard chemotherapy.
For: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)United States · Australia · Brazil - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
For: Advanced Non-small Cell Lung Cancer, HER2 MutationUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
This study looks at new drug combinations for advanced lung cancer. It combines telisotuzumab adizutecan with immune-boosting drugs like budigalimab or pembrolizumab. The goal is to find safe and effective doses to help people with non-small cell lung cancer who haven't had prior treatment for advanced disease.
For: Non Small Cell Lung CarcinomaUnited States · Belgium · China - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
For: Carcinoma, Non-Small Cell Lung · Squamous Cell Carcinoma of Head and Neck · HER2 Negative Breast NeoplasmsUnited States · France · South Korea - RecruitingPHASE3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
This study is looking at a new treatment for head and neck cancer that has come back or spread. It combines a new drug, amivantamab, with standard treatments to see if it works better than standard care alone to fight the cancer.
For: Squamous Cell Carcinoma of Head and NeckUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
This study is testing a new cancer medicine, AZD5335, on its own and with other treatments for various solid tumors. Researchers want to see if it's safe, tolerable, and if it can shrink tumors or stop them from growing. It's for people with advanced cancer.
For: Ovarian Cancer · Lung Adenocarcinoma · Endometrial CancerUnited States · Australia · Canada - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
This study looks at a new drug, mirvetuximab soravtansine, with carboplatin for certain types of ovarian, primary peritoneal, or fallopian tube cancer. It's for people whose cancer has come back but responded well to previous platinum-based chemotherapy.
For: High Grade Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube CancerUnited States · Belgium · Canada - Active not recruitingPHASE2
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment
This study looks at how a drug called carboplatin works for men with advanced prostate cancer. We want to see if changes in their genes affect how well the treatment works. It could help us find better ways to treat prostate cancer in the future.
For: Hormone Refractory Prostate CancerUnited Kingdom - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer (squamous non-small cell lung cancer) that has spread. It compares two different drug combinations, including a new medicine called rilvegostomig, to see if they can help patients live longer and improve their quality of life.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
This study is testing two different combinations of medicines, volrustomig plus chemotherapy, or pembrolizumab plus chemotherapy, for people with an advanced type of lung cancer. The aim is to see which combination is safer and works better as a first treatment.
For: Metastatic Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
For: Lung Neoplasms · Carcinoma, Non-Small-Cell LungUnited States · Argentina · Canada - Active not recruitingPHASE3
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
This study looks at treating a specific type of advanced lung cancer. It compares two treatments, atezolizumab alone or combined with lurbinectedin, after initial chemotherapy. The aim is to see which approach works best to keep the cancer stable.
For: Small-Cell Lung CancerUnited States · Belgium · Germany - RecruitingPHASE1, PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
This study looks at new ways to treat ovarian cancer that has come back after earlier treatments. It tests a new drug called Raludotatug deruxtecan (R-DXd) by itself or with other standard treatments, to see if it's safe and helps shrink the cancer.
For: Ovarian Cancer RecurrentUnited States · Israel · Spain - Active not recruitingPHASE3
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
This study compares two chemotherapy treatments for germ cell tumours that have returned or didn't respond to previous treatment. It looks at a standard chemotherapy plan versus a stronger plan with a stem cell transplant to see which works better.
For: Germ Cell Tumor · Teratoma · ChoriocarcinomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
This study compares a new combination medicine, BMS-986489 (BMS-986012 and Nivolumab), with a standard treatment (Atezolizumab), both given with chemotherapy. It's for people with a type of lung cancer called extensive-stage small cell lung cancer who are starting their first treatment.
For: Extensive-Stage Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
This study is for women with ovarian cancer that has come back, specifically a type that has responded well to chemotherapy in the past. It's looking at a new way to give carboplatin, a common chemotherapy drug, to see if it can work better and with fewer side effects.
For: Ovarian Cancer · Relapsed Ovarian Cancer · Fallopian Tube CancerUnited Kingdom - RecruitingPHASE2, PHASE3
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
This study looks for better ways to treat B-cell non-Hodgkin Lymphoma (B-NHL) in children and young people when initial treatments haven't worked or the cancer has returned. It tests new medicines to see if they are safe and effective, aiming to improve chances of recovery.
For: B-cell Non Hodgkin LymphomaAustralia · Austria · Belgium - Active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This study looks at new ways to treat a type of lung cancer before surgery. We're testing a drug called osimertinib, either alone or with chemotherapy, against chemotherapy by itself. The goal is to see if these new treatments can help more people with resectable non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Austria · Brazil